Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

This study is testing a combination of two drugs — sacituzumab tirumotecan (an antibody-drug conjugate that targets cancer cells) and limertinib (an EGFR-targeted drug) — given before surgery in patients with stage III non-small cell lung cancer (NSCLC) that has a specific mutation in a gene called EGFR. The goal is to shrink the tumor enough to allow surgery. **You may be eligible if...** - You have non-small cell lung cancer confirmed to have an EGFR mutation - Your cancer is locally advanced (stage IIIA, IIIB, or IIIC) and not yet suitable for immediate surgery - You have not received any prior cancer treatment - You are in good health (ECOG score 0–1) and your lungs can handle surgery - You are 18 or older **You may NOT be eligible if...** - You have had prior EGFR-targeted therapy or any TROP2 antibody-drug conjugate treatment - You are allergic to either study drug - You have a history of another primary cancer or organ transplant - You have active autoimmune disease or are on immunosuppressive steroids - You had major surgery in the 4 weeks before starting Talk to your doctor to see if this trial is right for you.